<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">However, few studies evaluate whether the observed effects arise from: (1) "therapeutic effect” of the prophylactic vaccination in leading to faster clearance of the residual infection; or (2) "primary prophylactic” effect of the vaccination on the newly developed lesions caused by new HPV infections after treatment; or (3) "secondary prophylactic” effect of the vaccination in reducing the ability of the residual virus to infect new cells. In this study, we explore the role of a bivalent vaccine in preventing secondary lesions and provide more scientific evidence for the impact of the vaccine on the women who are treated for cervical disease.</p>
